Observational studyClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Maternal, Pregnancy, and Infant Outcomes in Women Treated for Multidrug-Resistant/Rifampicin-Resistant Tuberculosis With Novel and Repurposed Drugs in KwaZulu-Natal, South Africa.
Observational study in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is limited information on the safety and efficacy of new and repurposed second-line anti-tuberculosis (TB) drugs in pregnant women.
methodsPregnant women initiating treatment for multidrug-resistant/rifampicin-resistant (MDR/RR) TB from 1 January 2018 to 31 March 2024 were included in this prospective, observational study. Maternal TB treatment and pregnancy outcomes were documented through ongoing record reviews and clinical assessments conducted to describe infant outcomes. Using Poisson regression with robust standard errors, we evaluated factors associated with favorable maternal treatment and pregnancy outcomes.
resultsOf 70 pregnant women treated for MDR/RR TB, 53 (76%) were diagnosed with human immunodeficiency virus (HIV). Favorable TB treatment outcomes were reported in 44 (62.9%) women. Sixty-seven (95.7%) of the 70 infants were born alive;median gestational age 38 weeks (interquartile range [IQR], 37.0-39.0) and median birth weight 2970 g (IQR, 2560-3280). All infants were exposed to bedaquiline. Twenty-three (34.3%) women had unfavorable pregnancy outcomes, with 20 (29.8%) infants born prematurely and/or with low birth weight. Women with positive sputum smears at treatment initiation were less likely to have a favorable treatment outcome (adjusted risk ratio, 0.33; 95% confidence interval, .17-.66; P = .002). Of the 43 infants evaluated at 12 months, 27 (62.8%) had favorable outcomes, with 10 (23.3%) infants developing TB in their first year of life.
conclusionsThe high TB-HIV coinfection rate is likely to have contributed to unfavorable pregnancy outcomes. Supportive maternal adherence counseling and infant TB preventive treatment are needed to prevent TB transmission to infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.